Navigation Links
LIAI completes world's most comprehensive analysis on influenza virus data

is on emerging infectious diseases, such as West Nile virus, along with those diseases considered potential bioterrorist threats. The database's influenza research was analyzed first due to the continuing problem of seasonal influenza and public health concerns over the possible spread of the H5N1 avian flu.

"The database marks the first time that all known antibody and T cell epitope information has been compiled in one place," said Sette, noting the searchable online database is freely available to scientists around the globe. "It gives researchers ways of sharing knowledge and information never available before. Previously, everyone did their own study, but would have no way of knowing if a particular epitope had been used one time, for example by a single individual responding to a single virus, or 100 different times. Now, scientists can search the database and find out all existing information on their particular topic. This will enable them to avoid unnecessary repetition and make faster progress toward new therapies and vaccines."

The database, publicly accessible at http://immuneEPITOPE.org, includes information culled from more than 100,000 separate research articles published over several decades, with the influenza information representing only a portion of the massive data set. "The influenza data shows that people have done a lot of work that gives important information as to how we respond to influenza virus," said Stephen Wilson, Ph.D., LIAI chief technology officer and project director of the database. "It also highlights those critical areas where we need to look further. The fact that we don't have a comprehensive vaccine for flu shows we have more work to do. This study shows us where we need to focus going forward."

For the influenza study, LIAI researchers analyzed information from 58 different influenza A virus strains, involving 600 different antibody and T cell epitopes
'"/>

Source:La Jolla Institute for Allergy and Immunology


Page: 1 2 3 4

Related biology news :

1. Worlds largest rainforest drying experiment completes first phase
2. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
3. Sandia completes depleted uranium study
4. PCRM develops worlds first cruelty-free insulin assay
5. Breakthrough: Scientists create worlds tiniest organic particles
6. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
7. Environmental lessons from tsunami as worlds coastal population doubles
8. New plant DNA libraries provides massive boost to worlds plant researchers
9. New book highlights worlds borderless conservation areas
10. Some good news for the worlds poor
11. New study of the worlds smallest elephant
Post Your Comments:
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" report ... One major trend upcoming in this ... biomedical applications. Chemical sensors help in recording of patient ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 11, 2010) Van Andel Research Institute (VARI) ... cells that line and protect the prostate in relation to ... that normal cells and cancer cells depend on different factors ... cancer cells without affecting normal cells when developing treatments. ...
... In its collective efforts to develop new drugs, the ... on the application of natural biological transformation processes. One ... microorganisms or cells in a bioreactor filled with a ... especially strict regulations, the conditions inside the bioreactor need ...
... When conditions become complicated, there is no choice but ... Some of them growing in mining areas have unusual strengths, ... and knowing how to deal with this. Based on this ... as medicinal herbs for contaminated soils. The current level ...
Cached Biology News:VAI researchers develop tool to help study prostate cancer 2Clean sampling from bioreactors 2Plants in mining areas can cure soil affected by contamination in very short time 2Plants in mining areas can cure soil affected by contamination in very short time 3
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three- and ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), Revenues for the third ... comparable period a year ago. The Company,reported a ...
... TNS Recovery Complex(R) and APS Corrective Complex(TM)-, ... Improvements in Skin Elasticity-, CARLSBAD, Calif., ... recent launch of TNS Essential Serum(TM) a ... two,cutting-edge treatments, TNS Recovery Complex(R) and APS ...
... New labeling reinforces strong safety profile of Ranexa ... a.m. ET/5:00 a.m. PT -, PALO ALTO, ... CVTX ) announced today that the U.S. Food ... line indication for,Ranexa(R) (ranolazine extended-release tablets) for the ...
Cached Biology Technology:EntreMed Reports Third Quarter 2008 Financial Results 2EntreMed Reports Third Quarter 2008 Financial Results 3EntreMed Reports Third Quarter 2008 Financial Results 4EntreMed Reports Third Quarter 2008 Financial Results 5SkinMedica Launches TNS Essential Serum(TM) 2SkinMedica Launches TNS Essential Serum(TM) 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 2FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 4FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 5